Gyu Yeul Ji1, Chang Hyun Oh2, Byung Gwan Moon3, Seong Yi4, In Bo Han5, Dong Hwa Heo6, Ki-Tack Kim7, Dong Ah Shin4, Keung Nyun Kim4. 1. Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Korea. ; Department of Neurosurgery, Guro Teun Teun Hospital, Seoul, Korea. 2. Department of Neurosurgery, Guro Teun Teun Hospital, Seoul, Korea. 3. Department of Neurosurgery, Eulji Hospital, Eulji University College of Medicine, Seoul, Korea. 4. Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Korea. 5. Department of Neurosurgery, Bundang CHA Medical Center, CHA University College of Medicine, Sungnam, Korea. 6. Department of Neurosurgery, The Leon Wiltse Memorial Hospital, Suwon, Korea. 7. Department of Orthopedic Surgery, Kyung Hee University College of Medicine, Seoul, Korea.
Abstract
OBJECTIVE: Epidural injection of hyaluronic acid may prevent adhesion formation after spine surgery, but the compounds used to stabilize hyaluronidase could interfere with its anti-adhesion effects. The present study was conducted as a clinical trial to evaluate the efficacy and safety of an experimental medical gel in preventing adhesion formation. METHODS: This study was designed as a multicenter, randomized, double-blind, and comparative controlled clinical trial with an observation period of 6 weeks. Subjects were randomly assigned into two groups: group A with sodium hyaluronate + 1,4-butanediol diglycidyl ether (BDDE) and group B with sodium hyaluronate + sodium carboxymethylcellulose (CMC). Visual analogue scale (VAS) of back and leg pain and the Oswestry disability index (ODI) and scar score ratings were assessed after surgery. RESULTS:Mean scar grade was 2.37±1.13 in group A and 2.75±0.97 in group B, a statistically significant difference (p=0.012). VAS of back and leg pain and ODI scores decreased significantly from baseline to 3 and 6 weeks postoperatively in both groups (p<0.001). However, VAS and ODI scores were not statistically different between groups A and B at baseline or at 3 and 6 weeks after operation (p>0.3). The number of adverse reactions related to the anti-adhesion gels was not statistically different (p=0.569), but subsequent analysis of nervous adverse reactions showed group B was superior with a statistically difference (p=0.027). CONCLUSION: Sodium hyaluronate with BDDE demonstrated similar anti-adhesion properties to sodium hyaluronate with CMC. But, care should be used to nervous adverse reactions by using sodium hyaluronate with BDDE.
RCT Entities:
OBJECTIVE: Epidural injection of hyaluronic acid may prevent adhesion formation after spine surgery, but the compounds used to stabilize hyaluronidase could interfere with its anti-adhesion effects. The present study was conducted as a clinical trial to evaluate the efficacy and safety of an experimental medical gel in preventing adhesion formation. METHODS: This study was designed as a multicenter, randomized, double-blind, and comparative controlled clinical trial with an observation period of 6 weeks. Subjects were randomly assigned into two groups: group A with sodium hyaluronate + 1,4-butanediol diglycidyl ether (BDDE) and group B with sodium hyaluronate + sodium carboxymethylcellulose (CMC). Visual analogue scale (VAS) of back and leg pain and the Oswestry disability index (ODI) and scar score ratings were assessed after surgery. RESULTS: Mean scar grade was 2.37±1.13 in group A and 2.75±0.97 in group B, a statistically significant difference (p=0.012). VAS of back and leg pain and ODI scores decreased significantly from baseline to 3 and 6 weeks postoperatively in both groups (p<0.001). However, VAS and ODI scores were not statistically different between groups A and B at baseline or at 3 and 6 weeks after operation (p>0.3). The number of adverse reactions related to the anti-adhesion gels was not statistically different (p=0.569), but subsequent analysis of nervous adverse reactions showed group B was superior with a statistically difference (p=0.027). CONCLUSION:Sodium hyaluronate with BDDE demonstrated similar anti-adhesion properties to sodium hyaluronate with CMC. But, care should be used to nervous adverse reactions by using sodium hyaluronate with BDDE.
Authors: Kee D Kim; Jeffrey C Wang; Daniel P Robertson; Darrel S Brodke; Erik M Olson; Arthur C Duberg; Mohammed BenDebba; Kathleen M Block; Gere S diZerega Journal: Spine (Phila Pa 1976) Date: 2003-05-15 Impact factor: 3.468
Authors: Peter J Richards; A Simon Turner; Serge M Gisler; Susan Kraft; Katja Nuss; Silke Mark; Howard B Seim; Jason Schense Journal: J Biomed Mater Res B Appl Biomater Date: 2010-02 Impact factor: 3.368
Authors: Jin-Yul Lee; Werner Stenzel; Peter Impekoven; Martin Theisohn; Hartmut Stützer; Mario Löhr; Thomas Reithmeier; Ralf-Ingo Ernestus; Heinrich Ebel; Norfrid Klug Journal: J Neurosurg Spine Date: 2006-07
Authors: J L Hinton; D J Warejcka; Y Mei; R E McLendon; C Laurencin; P A Lucas; J S Robinson Journal: Spine (Phila Pa 1976) Date: 1995-03-01 Impact factor: 3.468